The oral, non-steroidal mineralocorticoid receptor (MR) antagonist has been approved as Kerendia in the US – its first world market – to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalisation for heart failure in adults with CKD associated with type 2 diabetes.
Lying in wait on the market is AstraZeneca’s SGLT2 inhibitor Farxiga (dapagliflozin), which was approved to treat CKD patients earlier this year by the FDA, adding to an approval to treat heart failure that has consolidated its position in the diabetes armamentarium.
